FDA rejected to approve UCB IL-17A monoclonal antibody Bimekizumab
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
FDA rejected to approve UCB IL-17A monoclonal antibody Bimekizumab
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA rejected to approve UCB IL-17A monoclonal antibody Bimekizumab for treatment of moderate to severe plaque psoriasis.
On May 13, UCB announced that it had received the FDA’s Complete Response Letter (CRL) for the marketing application of Bimekizumab in the treatment of moderate to severe plaque psoriasis. Because the pre-market on-site inspection could not be completed, Bimekizumab could not be approved for marketing at present.
Bimekizumab was approved in the EU and UK in August 2021 for adults with moderate-to-severe plaque psoriasis suitable for systemic therapy and in Japan in January 2022 for the treatment of plaque in adults who have not responded adequately to existing therapies psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis. It will be approved in Canada and Australia in February and March 2022.
Bimekizumab is a humanized IgG1 mAb that binds to similar sites of IL-17A and IL-17F, while inhibiting IL-17A and IL-17F, a unique mechanism of action compared to other anti-IL-17A Drugs may have better efficacy. The BE RADIANT study of Bimekizumab was the first head-to-head trial of an anti-IL-17 drug and the first to demonstrate superiority to secukinumab in complete lesion clearance at both 16 and 48 weeks.
The current global IL-17 drug market size is nearly 7 billion US dollars, and Novartis Cosentyx (secukinumab) accounts for nearly 60%, about 4 billion US dollars.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
